On August 8 2023, NOVAVAX ($NASDAQ:NVAX) announced their financial results for the second quarter of fiscal year 2023, which concluded on June 30 2023. The company achieved a total revenue of USD 424.4 million, an increase of 128.3% compared to the same period in the previous year. Net income rose 111.4% year over year, to USD 58.0 million.
On August 8th, NOVAVAX reported its earnings results for the second quarter of FY 2023. The stock opened at $8.1 but closed the day at 7.2, down by 3.9% from its previous closing price of $7.5. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Novavax. NOVAVAX_Reports_Second_Quarter_FY_2023_Earnings_Results_on_August_8th”>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Novavax. NOVAVAX_Reports_Second_Quarter_FY_2023_Earnings_Results_on_August_8th”>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Novavax. NOVAVAX_Reports_Second_Quarter_FY_2023_Earnings_Results_on_August_8th”>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Novavax are shown below. NOVAVAX_Reports_Second_Quarter_FY_2023_Earnings_Results_on_August_8th”>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have conducted an analysis of NOVAVAX‘s health. Our Star Chart reveals that the company has a low health score of 2/10, which indicates that it may be less able to sustain future operations in times of crisis. Classified as a ‘rhino’ by our metrics, NOVAVAX has shown promise with moderate revenue or earnings growth. Given its weak performance in asset, dividend and profitability, NOVAVAX may not be the ideal option for conservative investors. However, its strong growth may make it an attractive opportunity for investors with a higher risk tolerance or those looking for long-term growth in the biopharmaceutical industry. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Novavax Inc and its competitors is fierce. Moderna Inc, BioNTech SE, and Pfizer Inc are all major players in the vaccine industry, and each company is striving to develop the most effective vaccine possible. While Novavax Inc has made great strides in recent years, its competitors are not far behind.
Moderna Inc is a clinical stage biotechnology company that discovers, develops, and commercializes therapeutics and vaccines based on RNA. As of 2022, Moderna Inc has a market cap of 48.32B and a ROE of 80.28%. Moderna Inc’s mission is to harness the power of RNA to revolutionize medicine and change the way diseases are prevented, treated, and cured.
As of 2022, BioNTech SE has a market cap of 32.44B and a Return on Equity of 71.82%. The company is a German biotechnology company that develops and manufactures vaccines and antibody therapeutics. The company has developed a platform that allows it to rapidly design and produce custom-made vaccines and therapeutics.
Pfizer Inc is a pharmaceutical company with a market cap of 247.45B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets safe, effective, and affordable human and veterinary medicines. The company is one of the world’s largest research-based pharmaceutical companies, with products available in more than 150 countries.
NOVAVAX reported impressive earnings results for the second quarter of FY2023, with total revenue reaching USD 424.4 million and net income up 111.4% year-over-year to USD 58.0 million. Despite these strong figures, the stock price fell on the same day. The reason behind this could be attributed to investor skepticism about the company’s long-term growth prospects, given its relatively small size and lack of exposure in the biotech industry. Nevertheless, its increasing revenue and profits suggest that NOVAVAX is capable of delivering strong returns to investors in the near future and could be a viable option for long-term investments.